Savara Inc. Stock price

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.98 USD +2.68% Intraday chart for Savara Inc. +1.84% +5.96%
Sales 2024 * - Sales 2025 * 10.07M Capitalization 688M
Net income 2024 * -68M Net income 2025 * -58M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 68.3 x
P/E ratio 2024 *
-12.8 x
P/E ratio 2025 *
-12.9 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.09%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.68%
1 week+1.84%
Current month-1.39%
1 month-2.16%
3 months+3.32%
6 months+31.75%
Current year+5.96%
More quotes
1 week
4.76
Extreme 4.76
5.00
1 month
4.52
Extreme 4.52
5.70
Current year
4.12
Extreme 4.115
5.70
1 year
1.63
Extreme 1.63
5.70
3 years
1.02
Extreme 1.02
5.70
5 years
0.69
Extreme 0.69
11.96
10 years
0.69
Extreme 0.69
17.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-04-26
Director of Finance/CFO 56 17-04-26
Chief Operating Officer 55 23-02-12
Members of the board TitleAgeSince
Director/Board Member 59 17-04-26
Director/Board Member 75 10-09-30
Director/Board Member 56 09-01-31
More insiders
Date Price Change Volume
24-03-28 4.98 +2.68% 904,349
24-03-27 4.85 -1.22% 356,280
24-03-26 4.91 +1.87% 647,226
24-03-25 4.82 +0.42% 447,221
24-03-22 4.8 -1.84% 557,186

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.98 USD
Average target price
8.786 USD
Spread / Average Target
+76.42%
Consensus
  1. Stock
  2. Equities
  3. Stock Savara Inc. - Nasdaq